Merck inks $493M biobucks deal to use Cyprumed's tech to create oral peptides
Merck will create oral versions of its peptides using Cyprumed's drug delivery technology through a non-exclusive license and option agreement that puts Cyprumed in line for up to $493 million.
Merck will create oral versions of its peptides using Cyprumed's drug delivery technology through a non-exclusive license and option agreement that puts Cyprumed in line for up to $493 million.
